Antibody Ingredients TRIZ Cases

PD-L1 tissue staining guides anti-PD-1 treatment selection, improving response prediction and durable cancer immunotherapy outcomes.

Tunable CD3-binding affinity helps bispecific antibodies preserve tumor cell lysis while reducing non-specific T-cell activation and cytokine release.

Chelating agents such as EDTA, DTPA, or citric acid help keep bispecific antigen-binding molecules stable at 8-35 mg/mL by reducing aggregation.

Engineered anti-B7H3 antibodies optimize CDR binding and humanized frameworks to improve cancer targeting while limiting immunogenicity.

By blocking PD-1/PD-L1 while bridging immune cells, these multispecific constructs boost T-cell activity and improve anti-tumor potency.

Protease- and acid-triggered anti-CTLA-4 activation at tumor sites boosts immune response while limiting systemic autoimmune toxicity.

Heavy chain-only anti-CD19 antibodies improve binding stability and affinity, enabling more specific treatment of CD19-expressing B-cell disorders.

Blocking SLIT2-ROBO2 signaling with anti-SLIT2 antibodies helps preserve podocyte function, reduce proteinuria, and protect kidney filtration.

Combining dUTPase inhibition with anti-PD-1 and thymidylate biosynthesis blockade helps overcome cancer resistance and improve tumor control.

Selective antibodies bind membrane-bound porcine CD163, avoid soluble CD163 neutralization, and inhibit PRRSV-1 and PRRSV-2 infection.

Direct joint injection of anti-CSF1R antibodies sustains local TGCT exposure, reduces serum levels, and helps avoid hepatotoxicity.

By blocking FGF7 and FGF10 binding to FGFR2b, this antibody suppresses tyrosine phosphorylation and tumor proliferation.

Using FLT3 agonist antibodies instead of soluble ligand expands dendritic cells and simplifies dosing by improving pharmacokinetic availability.

A SEZ6-targeting ADC delivers cytotoxic agents into small cell lung cancer cells to address relapse and resistance after chemotherapy.

By blocking TFPI-FXa interaction, this monoclonal antibody restores FXa generation and prolongs coagulation activity in hemophilia.

Targeting CD26 on activated T cells helps reduce steroid-resistant GvHD and promote stem cell engraftment after transplantation.

Dual-epitope HER2 antibodies improve clustering and lysosomal internalization, boosting efficacy in tumors with intermediate HER2 expression.

Selective CD47 binding boosts tumor-cell phagocytosis while limiting erythrocyte binding that can deplete antibody levels and cause anemia.

A ring-opened succinimide linker prevents premature payload release in ADCs, extending circulation time and reducing off-target toxicity.

Blocking FcRn accelerates clearance of pathogenic IgG autoantibodies, helping normalize thyroid function and reduce ablation need.

Specific anti-CDH17 antibodies improve CDH17-positive tumor targeting by combining high-affinity binding with internalization and immune cell killing.

Combining PD1-LAG3 checkpoint blockade with HLA-G T cell activation helps counter exhaustion and improve tumor-specific killing in cancer.

Selective DEspR inhibition clears dysregulated activated neutrophils to curb NET release, tissue injury, and organ dysfunction.

By binding the extracellular region of PTK7, this antibody bypasses active-site limits and suppresses angiogenesis and tumor cell spread.

Tumor antigen-dependent 4-1BB activation boosts tumor inhibition while limiting 4-1BB+ cell depletion and FcγR-linked toxicities.

A BCMA-GPRC5D-CD3 tri-specific antibody improves myeloma cell coverage while limiting CD3-driven cytokine release syndrome toxicity.

PDL1-targeted ADCs use linker-mediated intracellular drug release to improve tumor cell killing in dense tumors while lowering systemic toxicity.

Specific CDR-sequence antibodies target human CSF-1R with high affinity while limiting cross-reactivity and preserving inhibitory stability.

Conditional 4-1BB activation through CLDN18.2 binding boosts tumor immune response while limiting off-target liver toxicity.

Dual PD-1 and TIM-3 binding blocks immune inhibition and promotes synapse formation to strengthen anti-tumor response in advanced cancer.

Blocking CD5 signaling with defined antibody CDRs boosts IL-2, IFNγ, and Granzyme B to strengthen anti-tumor T cell activity.

Targets both human SIRPα-V1 and V2 while avoiding SIRPβ/γ binding, enabling broader tumor immunotherapy coverage with fewer off-target effects.

Selective Claudin 18.2 binding and improved endocytosis enable ADC delivery to tumors while avoiding Claudin 18.1 cross-reactivity.

RANKL blockade with denosumab plus PD-1 inhibition boosts T-cell anti-tumor responses in advanced melanoma without severe adverse events.

By blocking E-selectin-mediated adhesion, these antibodies reduce the duration, intensity, and severity of sickle cell VOC episodes.

Humanized and chimeric anti-TROP2 antibodies improve binding, endocytosis, and stability while reducing murine immunogenicity in tumor targeting.

A CD3×CD19 multispecific antibody format improves cancer-cell killing while extending half-life and easing manufacturability.

Enzyme-cleavable cyclic acetal linkers enable pH-independent, residue-free payload release in antibody-drug conjugates for tumor therapy.

Engineered bispecific CD19-CD3 antibodies combine dual cell targeting with improved stability, affinity, half-life, and B-cell depletion.

Combining a BCMA inhibitor with a CD38 antibody improves response depth in relapsed or refractory multiple myeloma despite added regimen complexity.

Antibodies that bind PILRA block ligand interaction and lower cell surface PILRA to activate myeloid cells in cancer and neurodegeneration.

IL-4R antagonist treatment controls bullous pemphigoid while reducing corticosteroid exposure, pruritus, and relapse risk.

Specific variable-region sequence changes improve mammalian expression of humanized anti-CEACAM5 antibodies without losing affinity or specificity.

Selective Siglec-15 targeting boosts antitumor immune response while reducing toxicity seen with broader PD-1/PD-L1 checkpoint therapies.

High-affinity CD16A binding helps NK cells resist receptor shedding, sustaining ADCC and tumor cell killing across cancers.

Covalently linked EV hydrogels improve tissue retention and sustained antigen presentation, supporting stronger tumor-specific CD8+ T cell responses.

Specific CDR sequence changes improve PD-1 binding and PD-1/PD-L1 blockade, boosting cytokine secretion and tumor growth inhibition.

A T cell-engaging IL-5Rα×CD3ε bispecific antibody drives eosinophil killing without increasing IL-5 half-life or relying on direct IL-5 blockade.

Engineered anti-CD47 and CD19 bispecific antibodies block SIRPα while limiting healthy-cell binding to improve safety and pharmacokinetics.

A dual PD-1/TIGIT binding protein boosts T cell activation and tumor cell killing in one antibody format, improving anti-tumor efficacy.

Segmented antibody domains resolve the trade-off between structural complexity and therapeutic efficacy by enabling simultaneous dual-target binding.

Self-stabilizing linker units prevent retro-Michael addition to maintain stereochemical integrity and reduce side effects.